Mostrar el registro sencillo del ítem
BAX and BAK proteins are required for cyclin-dependent kinase inhibitory drugs to cause apoptosis
dc.contributor.author | Garrofé-Ochoa, Xènia | |
dc.contributor.author | Melero Fernandez de Mera, Raquel Maria | |
dc.contributor.author | Fernandez Gomez, Francisco Jose | |
dc.contributor.author | Ribas, Judit | |
dc.contributor.author | Jordan, Joaquin | |
dc.contributor.author | Boix, Jacint | |
dc.date.accessioned | 2024-02-05T13:48:27Z | |
dc.date.available | 2024-02-05T13:48:27Z | |
dc.date.issued | 2008-12-03 | |
dc.identifier.citation | Garrofé-Ochoa, X., Melero-Fernández de Mera, R. M., Fernández-Gómez, F. J., Ribas, J., Jordán, J., & Boix, J. (2008). BAX and BAK proteins are required for cyclin-dependent kinase inhibitory drugs to cause apoptosis. Molecular cancer therapeutics, 7(12), 3800–3806. https://doi.org/10.1158/1535-7163.MCT-08-0655 | es |
dc.identifier.issn | 1538-8514 | |
dc.identifier.other | https://www.scopus.com/record/display.uri?eid=2-s2.0-57749087247&origin=inward&txGid=6367dcde4049246b5d980f8d93370290 | es |
dc.identifier.other | https://aacrjournals.org/mct/article/7/12/3800/93029/BAX-and-BAK-proteins-are-required-for-cyclin | es |
dc.identifier.other | https://watermark.silverchair.com/3800.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAzUwggMxBgkqhkiG9w0BBwagggMiMIIDHgIBADCCAxcGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMyHOQxyIt10w2wgW4AgEQgIIC6HVL-Kx6Rq-eXERNBO8r3TXLGdB2G7-hLS_UYGU3QXI1zBWRPCG7ofTafBe6t05BwzOf090rKkrZckcXOMSNEM31HSM91tKImdeDcfgYSYv7hcmJYu1GxPqgdK5XK3j_Dst3xr-NYnEP70CanVceHMPCdctzgWUHWIkN4UOYwDr79iFnVTk2YlFqWibAN32J6lIfZZe_DVmXeuHxUKzHV8cnN7Use7bIbIrj8OiyBIlSa1uGCW-Dp-gMunHLkUWaFHyUuEYyZmmpqYcKvkKCtUi6kl6SxHpGokGS1cJoMqGZuk61Ovp5TMHEOHoDmWOOINecmqABxAUgtaKELXgB4iGE4tCKEY4G8GGvWXahAnqiX1d_mqde7IHJBYKiVIRtz6LnCkERK_5wT3IB4s7LluWBZCzcVdbxhDxE-TM5lp3pDkCJHmjLXCXKnLbbrKg4bKqrZhhtqtyXhrzSN_ep_YpXgc0NK9o7hNCP_TZuzBYM36wt2lJjMndQ_zEOjUcZ5xItAz2GKgsrnlRG6ti0bDZdjVpYN7GKOtU5i87HS7RTFJuLkFMcHb_VUhQQXVtI94kdCVskvkouCBbc6VI2dliYGJ1c1msL81eXT90lTor1b-kiFviBhYI8nT0XFqldzWNWBw0_fbhVDL7xzKj2PDWOIf8Zj7WUvw4VdyMQBXauFkPio1cNh5HO7DxjdIqiZK5blEPaR23PhFdtyZOhQHcm_RfWcqRVX8-A3E_MhrFFjF0Vv_RGaRgIOYdraoRX3O_uD1-Z31gPqKtr43b4vu3LMOqCbJ_ZEhrYBhUJ2zRqqYzZ_nrQG8sNCxdojGbXterySmI1eNHk9LR4GNNEnAfVkUuuCXsJHx-zXa-e-lqUpmVbVvpHs7exh7lEjbXeuXug7jubZA51ZX4Kjrad0Xy4maYqus0PkJQ1JK1Pbr-sDrIEHV_iSMbo-j-w_tfAjGbf5CbBImCE4O_I9YHdhZoZMVW7PJdGCg | es |
dc.identifier.uri | http://hdl.handle.net/20.500.12020/1186 | |
dc.description.abstract | In previous reports, we have shown in SH-SY5 cells that olomoucine and roscovitine, two inhibitory drugs of cyclin-dependent kinases, caused apoptosis independent of the extrinsic pathway. In this experimental paradigm, apoptosis was refractory to the protective effects of either Bcl-2 or Bcl-XL overexpression. We are now reporting that the failure of Bcl-XL to prevent dell death was consistent with no effect on the kinetics of caspase activation and cytochrome c release. To further characterize this issue, we have discarded a direct effect of either olomoucine or roscovitine on mitochondrial permeability transition. Moreover, we have evidence that an intrinsic pathway took place in SH-SY5Y cells by showing the mitochondrial translocation of a GFP-Bax construct on transfection and treatment with cyclin-dependent kinase inhibitory drugs. Finally, we tested the effect of olomoucine and roscovitine on wild-type, bax-/-, bak-/-, and double bax-/-bak -/- mouse embryonic fibroblasts (MEF). In wild-type MEFs, both drugs induced cell death by apoptosis in a dose-dependent manner. In bax -/-, bak-/-, and, particularly, double bax -/-bak-/- MEFs, we observed the inhibition of apoptosis. In conclusion, olomoucine and roscovitine caused apoptosis through an intrinsic pathway, with Bax and Bak proteins being involved. | es |
dc.language.iso | en | es |
dc.publisher | American Association for Cancer Research | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | BAX and BAK proteins are required for cyclin-dependent kinase inhibitory drugs to cause apoptosis | es |
dc.type | article | es |
dc.identifier.doi | 10.1158/1535-7163.MCT-08-0655 | |
dc.issue.number | 12 | es |
dc.journal.title | Molecular Cancer Therapeutics | es |
dc.page.initial | 3800 | es |
dc.page.final | 3806 | es |
dc.rights.accessRights | openAccess | es |
dc.subject.area | Ciencias Biomédicas | es |
dc.subject.keyword | BAX | es |
dc.subject.keyword | BAK | es |
dc.subject.keyword | Proteins | es |
dc.subject.keyword | Mitochondrial permeability | es |
dc.subject.keyword | Caspase | es |
dc.subject.keyword | Cyclin dependent kinase | es |
dc.subject.keyword | Cytochrome C | es |
dc.subject.keyword | Apoptosis | es |
dc.subject.keyword | Enzyme activation | es |
dc.subject.unesco | 32 Ciencias Médicas | es |
dc.subject.unesco | 2302.04 Genética Bioquímica | es |
dc.volume.number | 7 | es |